Skip to Content


Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Cosmetic Product Voluntary Reporting Program

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 59073


Food and Drug Administration, HHS.




The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.


Fax written comments on the collection of information by November 10, 2005.


OMB is still experiencing significant delays in the regular mail, including first class and express mail, and messenger deliveries are not being accepted. To ensure that comments on the information collection are received, OMB recommends that comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: Fumie Yokota, Desk Officer for FDA, FAX: 202-395-6974.

Start Further Info


Peggy Robbins, Office of Management Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.

End Further Info End Preamble Start Supplemental Information


In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Cosmetic Product Voluntary Reporting Program—21 CFR Part 720 (OMB Control Number 0910-0030)—Extension

Under the Federal Food, Drug, and Cosmetic Act (the act), cosmetic products that are adulterated under section 601 of the act (21 U.S.C. 361), or misbranded under section 602 of the act (21 U.S.C. 362), cannot legally be distributed in interstate commerce. To assist FDA in carrying out its responsibility to regulate cosmetics, FDA requests under part 720 (21 CFR part 720), but does not require, that firms that manufacture, pack, or distribute cosmetics file with the agency an ingredient statement for each of their products. Ingredient statements for new submissions (§§ 720.1 through 720.4) are reported on Form FDA 2512, “Cosmetic Product Ingredient Statement,” and on Form FDA 2512a, a continuation form. Amendments to product formulations (§§ 720.3, 720.4, and 720.6) also are reported on Forms FDA 2512 and FDA 2512a. When a firm discontinues the commercial distribution of a cosmetic, FDA requests that the firm file Form FDA 2514, “Discontinuance of Commercial Distribution of Cosmetic Product Formulation” (§§ 720.3 and 720.6). If any of the information submitted on or with these forms is confidential, the firm may submit a request for confidentiality under § 720.8.

FDA places cosmetic product filing information in a computer database and uses the information for evaluation of cosmetic products currently on the market. Because filing of cosmetic product formulations is not mandatory, voluntary filings provide FDA with the best information available about cosmetic product ingredients and their frequency of use, businesses engaged in the manufacture and distribution of cosmetics, and approximate rates of product discontinuance and formula modifications. The information assists FDA scientists in evaluating reports of alleged injuries and adverse reactions from the use of cosmetics. The information also is used in defining and planning analytical and toxicological studies pertaining to cosmetics.

Information from the database is releasable to the public under FDA compliance with the Freedom of Information Act. FDA shares nonconfidential information from its files on cosmetics with consumers, medical professionals, and industry.

FDA has developed an electronic submission system for filing Forms FDA 2512, FDA 2512a, and FDA 2514 that will reduce the reporting burden for respondents and FDA. The system is currently undergoing additional beta testing and implementation is anticipated for fall 2005.

In the Federal Register of June 13, 2005 (70 FR 34142), FDA published a 60-day notice requesting public comment on the proposed extension of an existing collection of information described by the regulations in part 720. FDA received two letters, one from a trade association and one from a cosmetic company, each containing one or more comments, in response to the proposed extension of existing collection of information for part 720.

The trade association commended the agency for making the Cosmetic Product Voluntary Reporting Program less burdensome on the cosmetic industry by modernizing the program to take advantage of technological advances. The cosmetic company stated, however, that the requirement for both the ingredient name and a 9-digit identification number on Form FDA 2512a is burdensome.

FDA appreciates the trade association's remarks as well its assistance in making the voluntary reporting system more efficient. As to the burdensomeness of the dual requirement expressed by the cosmetic company, FDA expects to have its new system for electronic submission of cosmetic ingredient information to the Cosmetic Product Voluntary Reporting Program, which is currently in the beta testing stage, implemented in fall 2005. FDA expects that the new system will greatly simplify the submission of cosmetic ingredient information to the program by, among other things, permitting either the identification number or ingredient name to be submitted (except for new ingredients).

The cosmetic company also requested that FDA accept submission of a single Form FDA 2512 for groups of hair color preparations for which only the amounts of color additive ingredients are varied. FDA is not granting this request as it will be unnecessary once the agency implements its new electronic submission system. The agency's new electronic submission system will facilitate new submissions by making frequently used ingredients accessible from a “favorites” list and by making ingredient formulations previously submitted on the paper forms accessible to users of the new system upon proof of ownership.

The cosmetic company also requested that FDA modify the continuation footer in the paper version of Form FDA 2512a. FDA does not believe the requested change is necessary because the agency expects that its new electronic submission system will greatly reduce the use of paper versions of Forms FDA 2512, FDA 2512a, and FDA 2514.

The cosmetic company suggested that FDA revise the product categories in § 720.4(c) to include new types of products. FDA is not making the suggested revision. The agency does not believe this revision is necessary because each category already provides a subcategory for “other preparations” that covers products that do not fit in the specified subcategories.

Finally, the cosmetic company recommended that FDA's new electronic submission system provide for direct transfer of information from company databases to FDA's. FDA is not permitting this recommended direct transfer of information for security reasons. The agency has to limit the Start Printed Page 59074ways people can enter data into the electronic submission system to protect the database from corruption.

FDA estimates the burden of the collection of information as follows:

Table 1.—Estimated Annual Reporting Burden1

21 CFR SectionForm No.No. of RespondentsAnnual Frequency per ResponseTotal Annual ResponsesHours per ResponseTotal Hours
720.1 through 720.4 (new submissions)FDA 2512 and FDA 2512a11212.91,4460.5723
720.4 and 720.6 (amendments)FDA 2512 and FDA 2512a1120.5520.3317
720.3 and 720.6 (notices of discontinuance)FDA 2514112140.10.4
720.8 (requests for confidentiality)1111.51.5
1 There are no capital costs or operating and maintenance costs associated with this collection of information.

These estimates are based on FDA's experience with the Cosmetic Product Voluntary Reporting Program. The estimated annual total hours burden is 75 percent of the burden reported in 2002 due to decreased submissions. However, the number of respondents doubled, and FDA attributes this to increased interest in the program. FDA expects the number of submissions to increase accordingly in the next 3 years.

Start Signature

Dated: October 3, 2005.

Jeffrey Shuren,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 05-20307 Filed 10-7-05; 8:45 am]